Patents by Inventor Roger G. Ulrich

Roger G. Ulrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20200368243
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 26, 2020
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian J. LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20190083498
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 21, 2019
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • Therapies for hematologic malignancies
    Patent number: 10154998
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 18, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20170119771
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximah, and ofatumumab.
    Type: Application
    Filed: June 30, 2016
    Publication date: May 4, 2017
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Albert YU, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20170112841
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: September 27, 2016
    Publication date: April 27, 2017
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Langdon MILLER, Thomas M. JAHN
  • Therapies for hematologic malignancies
    Patent number: 9492449
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • Therapies for hematologic malignancies
    Patent number: 9238070
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 19, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20150196564
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 16, 2015
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE, Brian LANNUTTI, Albert YU, Langdon MILLER, Thomas M. JAHN
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20140323439
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 30, 2014
    Inventors: W. Michael GALLATIN, Roger G. ULRICH, Neill A. GIESE
  • NOVEL QUINOXALINE INHIBITORS OF PI3K
    Publication number: 20140235643
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of cancer and inflammatory diseases. In particular, the method comprises administration of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: October 4, 2012
    Publication date: August 21, 2014
    Inventors: Jerry B. Evarts, Kamal D. Puri, Roger G. Ulrich, Edward A. Kesicki, Thomas Judge
  • Treatment of liver disorders with PI3K inhibitors
    Patent number: 8691829
    Abstract: The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: April 8, 2014
    Assignee: Gilead Calistoga LLC
    Inventor: Roger G. Ulrich
  • ATROPISOMERS OF P13K-INHIBITING COMPOUNDS
    Publication number: 20130324561
    Abstract: The invention provides compounds, compositions and methods to treat certain inflammatory conditions or cancers by administering a compound that inhibits PI3K isoforms, wherein the compounds are optically active atropisomers. It provides optically active stereoisomers of a class of pyrazole-containing compounds, which are useful for these methods, and provides methods to obtain these compounds as well as pharmaceutical compositions containing these compounds.
    Type: Application
    Filed: September 23, 2011
    Publication date: December 5, 2013
    Applicant: GILEAD CALISTROGA LLC.
    Inventors: Jerry Evarts, Roger G. Ulrich
  • Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
    Patent number: 8440677
    Abstract: The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PI3K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: May 14, 2013
    Assignee: Gilead Calistoga LLC
    Inventors: Jerry B. Evarts, Roger G. Ulrich
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20130071323
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 21, 2013
    Applicant: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • COMBINATION THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20130064812
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and one or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 14, 2013
    Applicant: Gilead Calistoga LLC
    Inventors: W. Michael GALLATIN, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Albert Yu, Langdon Miller, Thomas M. Jahn
  • TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS
    Publication number: 20120178767
    Abstract: The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.
    Type: Application
    Filed: July 21, 2010
    Publication date: July 12, 2012
    Applicant: Gilead Calistoga LLC
    Inventor: Roger G. Ulrich
  • ATROPISOMERS OF 2-PURINYL-3-TOLYL-QUINAZOLINONE DERIVATIVES AND METHODS OF USE
    Publication number: 20100249155
    Abstract: The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PI3K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.
    Type: Application
    Filed: March 24, 2010
    Publication date: September 30, 2010
    Inventors: Jerry B. Evarts, Roger G. Ulrich
  • THERAPIES FOR HEMATOLOGIC MALIGNANCIES
    Publication number: 20100202963
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 13, 2009
    Publication date: August 12, 2010
    Inventors: W. Michael GALLATIN, Roger G. Ulrich, Neill A. Giese
  • Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
    Patent number: 6087377
    Abstract: The present invention provides a method for preventing or decreasing diarrhea associated with irinotecan administration comprising the administration of tamoxifen at least two cell cycles prior to irinotecan administration.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: July 11, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventor: Roger G. Ulrich
  • Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
    Patent number: 6040306
    Abstract: The present invention is a method of treating a person who has psoriasis or arthritis or reducing the toxicity of cancer chemotherapy which comprises administering to the patient an anti-psoriasis effective amount of an oxazolidinone, preferably (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]a cetamide.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: March 21, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Donald Herman Batts, Roger G. Ulrich